ITPHIGH SIGNALFINANCIAL10-K

ITP exhibits severe operational deterioration with dramatically reduced capital investment and substantially weakened cash generation capabilities.

The company's capital expenditure collapse from $22.3M to just $330K signals either severe liquidity constraints or a complete halt to growth investments, both concerning for a manufacturing business. Combined with meaningfully reduced operating cash flow and declining revenue, this suggests the company may be in distress or undergoing significant restructuring.

Comparing 2025-04-11 vs 2024-03-27View on EDGAR →
FINANCIAL ANALYSIS

ITP's financial position weakened notably across key metrics, with revenue declining 12.4% to $75.8M while SG&A expenses grew substantially to $14.8M, indicating deteriorating operational efficiency. The dramatic reduction in capital expenditure alongside reduced operating cash flow suggests either severe capital constraints or strategic retrenchment. While total liabilities decreased modestly and inventory levels were reduced, the overall picture signals a company under significant operational stress.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-98.5%
$22.3M→$330K

Capex reduced 98.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

SG&A Expense
P&L
+63.1%
$9.1M→$14.8M

SG&A up 63.1% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Operating Cash Flow
Cash Flow
-51.1%
$12.9M→$6.3M

Operating cash flow fell 51.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Accounts Receivable
Balance Sheet
-50%
$576K→$288K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Inventory
Balance Sheet
-33.8%
$3.6M→$2.4M

Inventory drawn down 33.8% — strong sell-through or deliberate destocking; watch for supply constraints.

Total Liabilities
Balance Sheet
-18.6%
$26.4M→$21.5M

Liabilities reduced 18.6% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
+14.3%
-$9.6M→-$8.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Revenue
P&L
-12.4%
$86.5M→$75.8M

Revenue softened 12.4% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2025-04-11
PRIOR — 2024-03-27
ADDED
As of April 11, 2025, there were 10,065,920 shares of the registrant s common stock, par value $0.001, issued and outstanding.
This annual report on Form 10-K includes our audited consolidated statements of income and comprehensive income and our audited consolidated balance sheets as of December 31, 2024 and 2023.
Based on our understanding of the current PRC law, we believe that we are currently not required to obtain any permission or approval from the China Securities Regulatory Commission ( CSRC ) and Cyberspace Administration of China ( CAC ) in the PRC to issue securities to foreign investors or continue listing of our company s securities on the NYSE American.
As of December 31, 2024, our variable interest entity accounted for an aggregate of 96.07% and 78.97% of our total assets and total liabilities.
As of December 31, 2024 and 2023, $6,948,799 and $3,705,111 of cash and cash equivalents were denominated in RMB, respectively.
For the year ended December 31, 2024, the major cash flows occurred between IT Tech Packaging, its subsidiaries and the VIE included (i) loans in the total amount of $1,059,480 provided by Dongfang Paper to Baoding Shengde; and (ii) repayment of shareholder loans in the total amount of $727,433 on behalf of IT Tech Packaging Inc.
For the year ended December 31, 2024, corrugating medium paper comprised approximately 100% of our total paper production quantities and roughly 99.82% of our total revenue.
Production of offset printing paper was suspended during the year ended December 31, 2024.
The machine supplier was delayed because the supplier extended the production schedule.
Tissue paper production was suspended during the year ended December 31, 2024.
REMOVED
As of March 27, 2024, there were 10,065,920 shares of the registrant s common stock, par value $0.001, issued and outstanding.
This annual report on Form 10-K includes our audited consolidated statements of income and comprehensive income and our audited consolidated balance sheets as of December 31, 2023 and 2022.
We believe that we are currently not required to obtain any permission or approval from the China Securities Regulatory Commission ( CSRC ) and Cyberspace Administration of China ( CAC ) in the PRC to issue securities to foreign investors.
As of December 31, 2022, our variable interest entity accounted for an aggregate of 88.54% and 72.59% of our total assets and total liabilities.
As of December 31, 2023 and 2022, $3,705,111 and $7,612,294 of cash and cash equivalents were denominated in RMB, respectively.
For the year ended December 31, 2023, the major cash flows occurred between IT Tech Packaging, its subsidiaries and the VIE included (i) loans in the total amount of $4,251,821 provided by Baoding Shengde to Tengsheng Paper; (ii) loans in the total amount of $2,834,547 from Baoding Shengde loans to Dongfang Paper; (iii) the payment in the amount of $5,491,139 made from Dongfang Paper to Baoding Shengde for purchase of raw materials; and (iv) funding through Shengde Holdings Inc.
to Qianrong, with an amount of $500,000 as capital contributions.
For the year ended December 31, 2023, corrugating medium paper comprised approximately 97.06% of our total paper production quantities and roughly 94.47% of our total revenue.
Revenue from offset printing paper was $3,215,190 with 5,573 tonnes sold for the year ended December 31, 2023.
Tissue paper products comprised approximately 0.52% of our total paper production quantities and approximately 1.51% of our total sales revenue for the year ended December 31, 2023.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →